Forlong Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
4
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$14.8M
- Investors
-
15
Forlong General Information
Description
Developer of cytokine therapeutics designed to treat cancer and other serious diseases through synthetic immunology. The company offers engineered cytokine drug platforms, immune cell activation technologies, and biomolecular discovery capabilities, enabling pharmaceutical and healthcare organizations to advance targeted immunotherapies with improved therapeutic potential.
Contact Information
Website
www.forlongbiotech.comCorporate Office
- Building 1, Suzhou Science and Technology Innovation Park
- Number 19 Yong'an Road, Hushu Pass Town
- Suzhou, Jiangsu 215000
- China
Corporate Office
- Building 1, Suzhou Science and Technology Innovation Park
- Number 19 Yong'an Road, Hushu Pass Town
- Suzhou, Jiangsu 215000
- China
Forlong Timeline
Forlong Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Later Stage VC | 01-Sep-2026 | $14.8M | Completed | Generating Revenue | ||
| 5. Later Stage VC | 04-May-2026 | Completed | Generating Revenue | |||
| 4. Early Stage VC (Series A1) | 29-Aug-2023 | Completed | Generating Revenue | |||
| 3. Early Stage VC (Series A) | 05-Feb-2023 | Completed | Generating Revenue | |||
| 2. Early Stage VC | 01-Nov-2021 | $4.67M | $4.67M | Completed | Generating Revenue | |
| 1. Seed Round | 10-Nov-2019 | Completed | Startup |
Forlong Patents
Forlong Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026105063-A1 | Long-acting il-15 agonist for treating bladder cancer | Pending | 14-Nov-2024 | ||
| WO-2025233861-A1 | Long-acting il-15 agonist for treating tumor | Pending | 08-May-2024 | ||
| US-20240076353-A1 | Agonistic interleiukin 15 complexes and uses thereof | Inactive | 31-Aug-2022 | ||
| US-20250136665-A1 | Agonistic interleiukin 15 complexes and uses thereof | Pending | 31-Aug-2022 | ||
| EP-4581060-A1 | Agonistic interleukin 15 complexes and uses thereof | Pending | 31-Aug-2022 | C07K14/7155 |
Forlong Signals
Forlong Investors (15)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Changshu Kaisheng Southeast Venture Capital Management | Growth/Expansion | Minority | ||
| Detong Capital | Venture Capital | Minority | ||
| Fosun Health Capital | Corporate Venture Capital | Minority | ||
| GF Xinde Investment Management | PE/Buyout | Minority | ||
| Shanghai Qingyun Private Equity Fund Management | Growth/Expansion | Minority |
Forlong FAQs
-
When was Forlong founded?
Forlong was founded in 2019.
-
Where is Forlong headquartered?
Forlong is headquartered in Suzhou, China.
-
What is the size of Forlong?
Forlong has 4 total employees.
-
What industry is Forlong in?
Forlong’s primary industry is Drug Discovery.
-
Is Forlong a private or public company?
Forlong is a Private company.
-
What is Forlong’s current revenue?
The current revenue for Forlong is .
-
How much funding has Forlong raised over time?
Forlong has raised $48.9M.
-
Who are Forlong’s investors?
Changshu Kaisheng Southeast Venture Capital Management, Detong Capital, Fosun Health Capital, GF Xinde Investment Management, and Shanghai Qingyun Private Equity Fund Management are 5 of 15 investors who have invested in Forlong.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process